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Rabia BegumIn the past few decades there has been a surge in initia-
tives to catalogue the diversity of the human micro-
biome, which have been rapidly followed by research
documenting the state of the microbiome in various hu-
man physiological states and geographical populations.
The evidence for a causal implication of the microbiome
in disease is compelling; our so-called second genome
could underlie a variety of complex diseases including
immunological, neurological and cardiovascular condi-
tions, as well as cancer. It is therefore not surprising that
the deep scrutiny of the normal microbiome and its
intersection with disease have drawn major scientific
and public interest.
In this special issue, Genome Medicine presents a col-
lection of articles describing novel insights into the func-
tional characterization of the human microbiome and
the shifts in microbiome composition in disease states
or recovery from disease. The issue also details the latest
advances in classifying individuals according to their
disease risk using computational approaches. For ex-
ample, Patrick Schloss and colleagues demonstrate that
a microbiota-based random forest model complements
existing screening methods to detect colonic lesions;
using this classification method, early stage colorectal
cancer may be detected in patients in a non-invasive
manner [1].
We also present the first study to develop a risk clas-
sification index for bacteremia from analysis of the fecal
microbiomes of patients with non-Hodgkin lymphoma
[2]. Dan Knights and colleagues present their approach
to predicting the risk of chemotherapy-related blood
stream infection in patients with cancer only on the
basis of their pre-treatment fecal microbiome, prior to
undergoing hematopoietic stem cell transplantation.
The researchers conclude that patients who are likely
to contract bacteremia can be identified before under-
going treatment. In a related review, Ying Taur and Eric
Pamer discuss how the microbiome mediates infectious
complications in patients with cancer and how to re-
duce infection risk in these patients [3].Correspondence: rabia.begum@genomemedicine.com
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to exploit the therapeutic potential of modulating the
microbiome. A review by Gautam Dantas and col-
leagues highlights the adverse effects of broad spectrum
antibiotics on the dynamics between healthy and
dysbiotic states; the authors expand upon the current
landscape of therapeutic approaches for precision
modulation of the microbiome and the advances made
so far in this area [4]. In another review, Linda Zhang
and Sean Davies discuss approaches to tap the thera-
peutic potential of key dietary metabolites that position
the microbiome towards a particular disease state [5].
These insights shed light on how we can utilize the
wealth of data extracted from microbiome research to
maintain a healthy microbiome and prevent disease.
This special issue aims to provide a current view of
the state of the field, including often forgotten compo-
nents of the microbiome such as the virome [6]. Build-
ing on these collective efforts to characterize diseases
and define disease risk, the field is moving towards
seeking a functional and mechanistic understanding of
how the microbiome produces a given phenotype. Only
then can we truly understand the intimate relationship
of the microbiome with health and disease, which will
aid in the race to design and develop more informed
diagnostic and therapeutic approaches.
We would like to express our deepest gratitude to
our Guest Editor, Curtis Huttenhower, for his invalu-
able advice and guidance in shaping this special issue.
We are also extremely grateful to the many reviewers
who provided feedback and advice.
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